Compare Johnson & Johnson (JNJ) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Kinder Morgan Inc — how do they compare? Johnson & Johnson trades at $260.76 (market cap $618.09B), while Kinder Morgan Inc trades at $32.35 (market cap $71.81B). The key difference: Johnson & Johnson is far larger — about 8.6× Kinder Morgan Inc's market cap, and Kinder Morgan Inc pays the higher dividend (3.66%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Kinder Morgan Inc for 150 Days on average.
| JNJ | KMI | |
|---|---|---|
Market Cap | $618.09B | $71.81B |
Volume | 6,050,983 | 16,921,908 |
Sector | Health | Energy |
52-Week High | $278.43 | $34.31 |
52-Week Low | $186.00 | $25.84 |
Typical Hold Time | 129 Days | 150 Days |
Enterprise Value | $646.37B | $103.86B |
Dividend Yield | 2.09% | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Kinder Morgan (KMI) trades at $32.36, up 1.7% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with revenue growth from $15.1B in 2024 to $16.9B in 2025 and consistent earnings beats, while maintaining a 19.31% net income margin. Recent news highlights the company's $6B-$7B growth pipeline and resilience in volatile energy markets.
KMI presents a compelling investment case with analyst consensus target of $37.20 (15% upside), strong dividend yield, and fee-based revenue model. Key risks include energy market volatility and high debt levels, but the company's project backlog and natural gas demand growth support positive long-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
